CanSinoBIO's Quadrivalent Meningococcal Conjugate Vaccine Menhycia® Receives Registration Approval in Argentina
核心洞察
CanSino Biologics' ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (Menhycia®) received drug registration approval from Argentina's ANMAT on June 25, 2026.
Argentina's meningococcal vaccine market, valued at USD 43.8 million in 2025, is projected to reach USD 74.6 million by 2033, representing a CAGR of 6.3%.
Menhycia® is the first quadrivalent meningococcal conjugate vaccine approved in China, offering protection against serogroups A, C, Y, and W135 with stronger immune responses and longer-lasting protection.
CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced on June 25, 2026, that its ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) — marketed under the trade name Menhycia® — has received a drug registration certificate from Argentina's Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). The approval marks a significant expansion of the company's international footprint in South America and underscores the growing global demand for advanced meningococcal immunization.
Strategic Market Entry in South America
Argentina was selected based on favorable market fundamentals and strategic importance. According to market research firm Grand View Research, Argentina's meningococcal vaccine market was valued at approximately USD 43.8 million in 2025 and is projected to reach USD 74.6 million by 2033, reflecting a compound annual growth rate (CAGR) of 6.3%. The introduction of Menhycia® is expected to improve access to high-quality meningococcal immunization in the country while aligning with growing regional demand.
The approval also reflects the effectiveness of CanSinoBIO's internationalization strategy, which advances through diversified cooperation models including technology transfer, intermediate product supply, and finished product supply. The company has identified Southeast Asia, the Middle East, North Africa, and South America as key markets for expansion.
Clinical Profile of Menhycia®
Menhycia® is the first quadrivalent meningococcal conjugate vaccine approved in China. It is designed to prevent meningococcal disease caused by Neisseria meningitidis (搜索) serogroups A, C, Y, and W135. The vaccine has demonstrated significant clinical advantages, including stronger immune responses, longer-lasting protection, and the ability to reduce bacterial carriage. Currently, Menhycia® is approved in China for use in children aged 3 months to 6 years (83 months).
CanSinoBIO has completed clinical studies for age expansion of Menhycia® to cover individuals aged 7 to 59 years and has obtained the clinical summary report. The company is actively pursuing supplementary applications, which are expected to further broaden the product's target population coverage.
Global Public Health Context
Meningococcal meningitis (搜索) is a severe infectious disease characterized by rapid onset and severe progression, posing significant health risks particularly to infants and children. The World Health Organization's Defeating Meningitis by 2030: A Global Road Map sets ambitious targets to reduce vaccine-preventable bacterial meningitis cases by 50% and deaths by 70% by 2030, compared with 2015 levels. Against this backdrop, a significant supply gap for innovative vaccines remains. As Asia's first quadrivalent meningococcal conjugate vaccine, Menhycia's international expansion aligns directly with the WHO's meningitis prevention and control agenda.
Broader Strategic Implications
CanSinoBIO is transitioning from exporting individual products to delivering technology, manufacturing know-how, and production capabilities to international markets. The Argentina approval demonstrates the company's growing synergies across innovation, regulatory registration, manufacturing and supply capabilities, and commercialization. This milestone provides additional validation of CanSinoBIO's globalization strategy and valuable experience for the future international expansion of its innovative product portfolio.